



AUSTRALIA'S Vaccine Value Chain

CONFERENCE

21st – 22nd May 2024
Doltone House Hyde Park
Sydney, NSW

Draft Program

Proudly brought to you by



Sponsors

Diamond sponsor



Platinum sponsor



Gold sponsors



Silver sponsors



Bronze sponsors



Government of South Australia



Contributors



Program Committee

We are proud to develop an inaugural program that will showcase all elements of the vaccine value chain. Please note that this draft program is subject to change.



Jenny Herz

Co-founder and
Strategic Advisor,
Biointellect




Branwen Morgan

Lead,
Minimising AMR Mission
Research Director,
Health & Biosecurity, CSIRO



Jodie McVernon

Professor and Director of
Doherty Epidemiology
Head, VIDRL Epidemiology
Unit, Department of
Infectious Diseases



John Skerritt

Enterprise Professor for
Health Research Impact,
University of Melbourne



Ian Henderson

Executive Director,
Institute for Molecular
Bioscience, UQ



David Grolman

Medical mRNA
and Antiviral Lead,
Pfizer Australia



Alma Fulurija

Head of Strep A Vaccines
Telethon Kids



Leanne Hobbs

Independent consultant

The Program Committee would like to thank Kieran Schneemann for his contribution to the organisation of this event.

Program Summary – Day 1

Tuesday 21st May 2024

8:00am – 8:30am	Registration Coffee, Tea and Refreshments
8:30am – 8:50am	Opening of the Conference Welcome to Country and Opening Remarks Speakers: Brett Sutton , Director Health & Biosecurity, CSIRO Jennifer Herz , Co-Founder & Director, Biointelect
8:50am – 10:15am	Plenary 1: The Vaccine Value Chain – What Do We Want for Australia? Session Moderator: Steve Wesselingh , Chief Executive Officer, National Health and Medical Research Council This session will introduce the concept of the vaccine value chain, present insights from successful international models, the Australian experience and discuss how we can measure and improve research impact and commercialisation. <ul style="list-style-type: none">• Vaccine Value Chain and Global Ecosystem Eric Claassen, Chief Executive Officer, Vironovative BV Linda van de Burgwal, Associate Professor Societal Entrepreneurship and Innovation in Health and Life Sciences, Athena - Research and Education Institute• BactiVac - The UK Network Enabling Clinical Trials for AMR Adam Cunningham, Co-Director, Bacterial Vaccine Network (BactiVac)• Australian Ecosystem for Commercialisation of Vaccines – Where Are They Now? Jennifer Herz, Co-founder & Director, Biointelect Esther Pronker, Consultant, Biointelect• The UK Vaccine Network and Comparison with Australia Alex Spencer, Immunology Lecturer, University of Newcastle Panel Discussion: The Vaccine Value Chain: How does Australia compare? Where to Play How to Win
10:15am – 10:45am	Morning Tea and Networking

10:45am – 12:00pm	<p>Plenary 2: Preclinical Vaccine Development Capabilities in Australia: Governance, Skills and Talent</p> <p>Session Moderator: Ian Henderson, Executive Director, Institute for Molecular Bioscience, University of Queensland</p> <p>This session explores pre-clinical vaccine development in Australia including some of our unique strengths, highlights the challenges in funding, skills and governance and includes some local and international models as exemplars for change.</p> <ul style="list-style-type: none">• Overseas Example CARB-X Accelerator and Learnings Richard Alm, Chief Scientist Officer, Carb-X• What's New in Optimising Preclinical Vaccine Research Deborah Burnett, Group Leader, Garvan Institute of Medical Research• Attracting Industry Investment in R&D, the Translational Science Hub as an Example Iris Depaz, Managing Director Translational Science Hub, Sanofi• Health Security Systems Australia: Reflections from Medical Countermeasures Program and Australian capability Audit Felicia Pradera, General Manager, Health Security Systems Australia <p>Panel Discussion: Where Can We Get the Best Bang for Our Buck to Enable Pre-Clinical Research Translation to the Clinic?</p> <ul style="list-style-type: none">• Invited panelist Tony Cunningham, Director, Centre for Virus Research, The Westmead Institute for Medical Research
12:00pm – 1:00pm	Lunch and Networking Event

1:00pm – 2:15pm

Plenary 3: Clinical Trials and Infrastructure

Session Moderator: **Kylie Sproston**, Chief Executive Officer, Bellberry Limited

This session will provide different perspectives on clinical trial capability, from industry, academia, NGOs, and from early stage trials through to large phase 3 international trials. The panel will discuss how Australia can grow its global share of vaccine trials and attract industry investment as well as improve access for underserved populations

- **Australian Capability and Contribution to Clinical Trials**

Peter Richmond, Head, Vaccine Trials Group, Telethon Kids Institute

- **Australia's Strengths in Early Phase Trials and Capability Gaps**

Paul Griffin, Director of Infectious Disease, Mater Hospital

- **Clinical Development Challenges in Global Clinical Trials, What Do Sponsors Look For?**

Cheryl Keech, Consultant in Strategic Clinical Development

- **Regional Clinical Trial Capability and Impact on Policy in Asia-Pacific**

Fiona Russell, Group Leader Asia-Pacific Health Research, Murdoch Children's Research Institute

Panel Discussion: How To Leverage Existing Vaccine Clinical Trial Capability, Grow Global Share, Attract Industry Investment and Do More to Reach Underserved Populations

- **Invited panelist**

Craig Rayner, Director Regional Research Centre for Respiratory Medicines and Tropical Diseases, Moderna

2:15pm – 3:30pm	<p>Plenary 4: Manufacturing: Supply, Demand and Sustainability</p> <p>Session Moderator: Sue MacLeman, Advisor and Non Executive Director, Medical Technology and Pharmaceutical (MTP) Sector</p> <p>This session will outline the goals of the NRF and the strategic importance of Sovereign Manufacturing, before moving on to explore different perspectives from industry with respect to supply chain and manufacturing. It then critically examines the pressing challenges and central issues surrounding the supply and demand dynamics of vaccines, emphasising the balance of local and global strategies for a robust and resilient vaccine ecosystem for the future.</p> <ul style="list-style-type: none">• Perspective on the Government Investment and Current/Planned Australian Manufacturing Capability Ivan Power, Chief Executive Officer, National Reconstruction Fund Corporation• Local Manufacturer’s Perspective on Supply, Demand, and Sustainability Chris Larkins, Vice President - Operation, CSL Seqirus• Global Supply Chain Perspective on Supply, Demand, and Sustainability Sacha Kersten, Senior Director, APAC Customer Fulfillment Lead, Pfizer• Biotech Perspective on Supply, Demand, Sustainability and Logistics of Delivery Angus Forster, Chief Technology Officer, Vaxxas <p>Panel discussion: Getting the Balance Right: Sovereign Capability, Regional Security and the Global Supply Chain</p>
3:30pm – 4:30pm	Afternoon Tea and Networking

<p>4:00pm – 5:30pm</p>	<p>Plenary 5: Enabling Policy and Regulation for Vaccines Session Moderator: Jodie McVernon, Professor and Director of Doherty Epidemiology</p> <p>This session offers an update from the Department of Health and Aged Care, delves into the enabling regulations for cutting-edge platform technologies, particularly highlighting the potential of mRNA for human and veterinary vaccines. It also provides insights into the latest developments in the National Immunisation Strategy and underscores the relationship between evidence-based evaluation, public and animal health policies and the regulation of vaccines.</p> <ul style="list-style-type: none"> • Update on the National Immunisation Strategy and reflections from the Pandemic Paul Kelly, Chief Medical Officer, Australian Government Department of Health and Aged Care • The Platform Approach for Facilitating Vaccine Development and Regulation: mRNA as an Example John Skerritt, Enterprise Professor for Health Research Impact, University of Melbourne • Vaccine Surveillance and Vaccine Safety Kristine McCartney, Director, National Centre for Immunisation Research & Surveillance • Industry Perspectives on Pandemic Learnings and Enabling Regulatory Pathways Carolyn Tucek-Szabo, Senior Director Global Regulatory Sciences Lead Australia/ New-Zealand, Moderna • Animal Health Vaccines: Regulatory Barriers and Opportunities for Alignment Ben Stapley, Chief Executive Officer, Animal Medicines Australia <p>Panel Discussion: How Can Policy and Regulation Better Enable the Value Chain, Role of International Harmonisation, Learnings from Pandemic, One Health Opportunities for Alignment</p>
<p>6:00pm – 7:00pm</p>	<p>Pre-dinner Drinks</p>
<p>7:00pm – 10:00pm</p>	<p>Dinner and Evening Networking Venue: Strangers Foundation Room, NSW Parliament</p> <p>Welcome Speaker: Leah Goodman, Chief Executive Officer, Biointelect</p> <p>Dinner Address Speaker: The Hon. Anoulack CHANTHIVONG, BComm, MEc, MSc, MP Minister for Industry and Trade, Minister for Innovation, Science and Technology, Minister for Better Regulation and Fair Trading, Minister for Building, and Minister for Corrections</p>

Program Summary – Day 2

Wednesday 22nd May 2024

8:00am – 8:30am

Coffee, Tea and Refreshments

8:30am – 9:45am

Special Session: How Can Australia Contribute to Advance CEPI's 100 Day Mission and the Regional Vaccine Manufacturing Collaborative?

Session Moderator: TBC

- **Update from CEPI (recorded presentation)**

Frederik Kristensen, Managing Director Regionalized Vaccine Manufacturing Collaborative (RMVC)

Australia Case study Series

- **Case Study One**

Keith Chappell, Professor, Australian Institute for Bioengineering and Nanotechnology, the University of Queensland

- **Case Study Two**

Jamie Triccas, Deputy Director, Sydney Infectious Diseases Institute, The University of Sydney

- **Case Study Three**

Anne Collins, Chief Executive Officer, Sementis

Panel Discussion

9:45am – 11:00am	<p>Plenary 6: Equity of Access and Uptake</p> <p>Session Moderator: Rodney Pearce, Chair, Immunisation Coalition</p> <p>This session delves deep into Australia’s pivotal role and challenges in vaccine distribution and advocacy, drawing lessons from the COVID-19 pandemic and insights from CEPI. It also sheds light on the prevalent issue of vaccine hesitancy, with lessons learned from Australia’s HPV campaign. Furthermore, the session examines adult vaccine uptake, particularly focusing on the unique challenges of delivering vaccines underserved and hard to reach populations and the need for evidence informed approaches to privileging access to achieve equitable health outcomes.</p> <ul style="list-style-type: none">• Improving Vaccine Confidence, Equity and Uptake (in Australia and the Asia Pacific region) Margie Danchin, Deputy Chair, Australian Regional Immunisation Alliance• Examples of Access Barriers GP Perspective Nigel Stocks, Director, Australian Sentinel Practices Research Network• Pharmacy Role in Increasing Adult Vaccine Uptake – Pilots in Queensland and New Initiatives for Travel Vaccinations Chris Campbell, General Manager, Policy and Program Delivery• Achieving Equity in Underserved Populations Kristy Crooks, Aboriginal Program Manager and leads Public Health Aboriginal Team, Health Protection- Hunter New England <p>Panel Discussion: Priorities to Improve Access, Uptake and Address Vaccine Hesitancy</p>
11:00am – 11:30am	Morning Tea and Networking

11:30am – 12:45pm

Plenary 7: Market Access and Health Technology Assessment

Session Moderator: **Katrina Lapham**, Director, Strategic Market Access & Policy, Biointelect

This session presents the latest findings from the Health Technology Assessment (HTA) review and discusses the specific considerations of vaccines within the HTA framework. It delves into the challenges of access delays, related to evidence, systems and processes, offering a comparative perspective with overseas practices and emphasizing the community's viewpoint on the value of vaccines.

- **Perspectives on How Vaccines are Valued**

Natalie Carvalho, Associate Professor of Health Economics, Melbourne School of Population and Global Health, University of Melbourne

- **Clinical Research Perspectives on HTA, Value of Vaccines and Evidence Generation**

Michelle Giles, Professor Department of Infectious Disease, University of Melbourne

- **Industry Perspectives On HTA Review Priorities for Vaccines**

Andrew Thirlwell, Global Policy and Public Affairs, Australia, New-Zealand and Korea Lead, Pfizer

- **Issues Raised By Stakeholders and Experts in the HTA Review, and How These Have Been Considered**

TBD

Panel Discussion:

- **Do we value vaccines appropriately? What are we doing right? Where is there room for improvement? What could all stakeholders do (including product developers/sponsors) to improve?**
- **What are the opportunities from harmonisation? Are there lessons from Europe? Are there practical challenges in harmonising HTA when there are differences in underlying burden of infectious diseases and attitudes to vaccination across countries?**
- **Systems and data gaps and uncertainty**
- **Do we do a good job of considering access issues, equity and implementation challenges in HTA for vaccines? How can we better integrate these areas of the system to improve public health outcomes?**

12:45 – 1:45pm

Lunch and Networking

1:45 – 3:00pm

Plenary 8: Funding and Investment

Session Moderator: **Chris Smith**, Partner, Brandon Capital

This session opens with strategies for financing vaccine commercialisation and spurring new innovations. It then ventures into the challenge of stimulating vaccine development for diseases that offer limited financial returns. The session underscores the role and potential of Public-Private Partnerships within Australia and concludes with a critical examination of where funding and investment should be channelled to ensure optimal outcomes for both Australia and the broader region.

- **Government Investment Update and/or Research Investment (recorded presentation)**

Pru Glasson, Director Translation and Commercialisation Section, Australian Government Department of Health and Aged Care

- **How Industry Makes Investment Decisions**

Patrick Desbiens, Senior Vice President & General Manager Australia, GSK

- **Accelerating vaccines with limited commercial potential – the Strep A example**

Jonathan Carapetis, Executive Director, Telethon Kids Institute

- **Global Venture Capital and Private Equity Investment**

Eric Claassen, Chief Executive Officer, Vironovative BV

Panel Discussion:

3:00 – 3:40pm

Plenary 9: Bringing it All Together/The Vaccine Value Chain

Session Moderator: **Darren Saunders**, Deputy Chief Scientist & Engineer Executive Director, Office of the Chief Scientist & Engineer

The final interactive session will round off the conference by bringing all the discussions together to review the key areas within the Australian vaccine value chain. This session is envisaged as a round-table to give attendees the opportunity to reflect on various parts of the end-to-end process.

Panel Discussion:

- **Panelists**

Jodie McVernon, Professor and Director of Doherty Epidemiology

Kylie Sproston, Chief Executive Officer, Bellberry Limited

Sue MacLeman, Advisor and Non Executive Director, Medical Technology and Pharmaceutical (MTP) Sector Chief Executive Officer, Bellberry Limited

Ian Henderson, Executive Director, Institute for Molecular Bioscience, University of Queensland

Chris Smith, Partner, Brandon Capital

<p>3:40 – 3:50pm</p>	<p>Closing Remarks</p> <p>Speaker: The Hon. Anoulack CHANTHIVONG, BComm, MEc, MSc, MP Minister for Industry and Trade, Minister for Innovation, Science and Technology, Minister for Better Regulation and Fair Trading, Minister for Building, and Minister for Corrections</p>
<p>4:15 – 5:30pm</p>	<p>CSIRO SATELLITE SESSION: Advancing Innovation in Australian Veterinary Vaccines</p> <p>Session Moderator: Branwen Morgan, Lead Minimising Antimicrobial Resistance Mission, CSIRO</p> <p>The advent and use of new technologies and platforms has significantly expedited vaccine development with the ability to rapidly target new diseases. This creates opportunities to streamline product development and regulatory pathways. The objective of this session is to identify ways for Australia to keep pace with these advances and to deliberate current innovations and future trends for veterinary vaccines.</p> <ul style="list-style-type: none"> • Pathways for developing mRNA vaccines for animal health Paul Hick, Research Coordinator, Veterinary Virology, Elizabeth Macarthur Agricultural Institute (EMAI), NSW Department of Primary Industries (NSW DPI) • Veterinary Vaccines for Australia – Zoetis Perspectives Kishore Prayaga, Director, Zoetis • Veterinary Vaccines for Australia – Bioproperties Perspectives Robin Achari, Senior Technical Veterinarian, Bioproperties • Biosecurity Policy Review: A Secure Future for Imports of Veterinary Vaccines Nathan Jamieson, Director, Department of Agriculture, Fisheries and Forestry (DAFF) Animal and Biological Import Branch • Regulatory Approaches for Veterinary Vaccine Platform Technologies – Challenges and Opportunities Mariette van den Berg, Regulatory Scientist, Australian Pesticides and Veterinary Medicines Authority <p>Panel Discussion</p>



Biointelect Pty Ltd ABN 17 154 647 051

Level 4, 143 Macquarie Street, Sydney NSW Australia 2000

Level 17, 31 Queen Street, Melbourne VIC Australia 3000

T 1300 800 984 E events@biointelect.com 

The CSIRO logo and acronym are trade marks of CSIRO and used under licence.